– USA, CA – Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced the appointment of Jim Kelly to its Board of Directors.
“We are pleased to welcome Jim Kelly to the Theravance Board of Directors. Weiss Asset Management has been one of our largest shareholders since 2021, and Jim has extensive investment experience as well as a thorough understanding of our industry, our Company and the communities we serve. We believe Jim’s perspective, knowledge of the capital markets and deep financial acumen are highly valuable to, and further strengthen, our Board as we continue to execute on our strategy and seek to maximize value for all of our shareholders,” said Chairman and CEO, Rick Winningham.
About Jim Kelly
Jim Kelly is Managing Director at Weiss Asset Management, the second-largest shareholder of Theravance, and a member of the firm’s Investment Committee. Mr. Kelly has nearly twenty years of experience as a professional investor in the public and private markets and a decade of experience investing in healthcare. Prior to joining Weiss Asset Management, Mr. Kelly was an analyst at Farallon Capital Management, Madison Dearborn Partners, and Lehman Brothers. Founded in 1991 and based in Boston, Weiss Asset Management has approximately $3 billion in assets under management.
“I am excited to join the Board of Directors of Theravance Biopharma,” said Jim Kelly. “I am personally devoted to the success of this Company, and I am committed to leveraging my experience to support the Company in achieving its full potential. I look forward to working collaboratively with my fellow Board members and management to drive continued success for the Company and deliver short- and long-term growth and shareholder returns.”
About Theravance Biopharma
Theravance Biopharma, Inc.’s focus is to deliver Medicines that Make a Difference in people’s lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of an FDA-approved YUPELRI inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension, has the potential to be a first-in-class therapy effective in treating a constellation of cardinal symptoms in multiple symptom atrophy patients. The Company is committed to creating/driving shareholder value.
Source: https://www.theravance.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
